AGC Biologics’ Milan site continues to solidify its reputation as a global leader in cell and gene therapy with its recent 10th product approval from the EMA and FDA. With a 30-year track record of success, the team at AGC Biologics Milan has deep expertise in handling complex projects in the field.
They have successfully guided numerous products to commercial stages, manufactured hundreds of batches for clinical supply, and consistently met the highest global regulatory standards. The recent approval of AUCATZYL® for the treatment of r/r B-ALL further highlights the site’s commitment to quality and reliability in the industry. The partnership between Autolus Therapeutics and AGC Biologics Milan showcases a true collaboration in achieving regulatory success and commercial-scale manufacturing for global markets.
Read more on finance.yahoo.com